Fertility in Male Patients Treated With Neoadjuvant Chemotherapy for Osteosarcoma : Journal of Pediatric Hematology/Oncology

Secondary Logo

Journal Logo


Fertility in Male Patients Treated With Neoadjuvant Chemotherapy for Osteosarcoma

Longhi, Alessandra M.D.; Macchiagodena, Michele M.D.; Vitali, Giovanni M.D.; Bacci, Gaetano M.D.

Author Information
Journal of Pediatric Hematology/Oncology 25(4):p 292-296, April 2003.



To evaluate fertility in male patients with osteosarcoma after chemotherapy including high doses of alkylating agents.

Patients and Methods 

Postchemotherapy fertility was evaluated in 96 male patients who received chemotherapy at the authors' institution from 1976 to 1996 for localized bone osteosarcoma of the extremities. Four drugs were administrated (doxorubicin, cisplatin, methotrexate, ifosfamide) at different doses according to six different protocols. Eleven patients were prepubertal and 85 were postpubertal at the time of chemotherapy. The median age of these patients at the time of chemotherapy was 17 years (range 10–42), the median age at the time of the interview was 27 years (range 19–53), and the median follow-up from the end of chemotherapy was 9 years (range 4–17).


Of the 96 patients, 26 underwent sperm analysis and 20 showed oligo- or azoospermia. Patients who received high-dose ifosfamide showed a higher incidence of azoospermia. Six patients were normospermic and received no ifosfamide or lower doses of ifosfamide. Eight patients fathered a total of 12 children. No birth defects or congenital anomalies were observed in their offspring.


The rate of sterility was related to ifosfamide dosage. It appears that pubertal maturation is not affected by chemotherapy. No congenital malformations were seen in the children of the few patients who fathered children.

© 2003 Lippincott Williams & Wilkins, Inc.

You can read the full text of this article if you:

Access through Ovid